considering the end before the beginning: choosing the correct endpoints - andreas grauer, amgen
TRANSCRIPT
![Page 1: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/1.jpg)
Considering the End before the Beginning: Choosing the Correct EndpointsChoosing the Correct Endpoints
Andreas Grauer, MDExecutive Medical DirectorActing Therapeutic Area Head Global Development – Bone and NephrologyGlobal Development LeaderpAmgen Inc
![Page 2: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/2.jpg)
Disclaimer
• The views expressed herein represent those of the t d d t il t th ipresenter and do not necessarily represent the views or
practices of the presenter’s employer or any other party.
2
![Page 3: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/3.jpg)
…to get from Bench to Bedside requires to keep the end in mind…p
Research /Research / Academia &
IndustryTranslational
SciencesGlobal
Development Commercialization
Formulate a hypothesis based on insights into
biology
Test hypothesis in people
Take the best to market
Ensure patients have access to the
medicine
![Page 4: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/4.jpg)
The Drug Development Processg p
A tremendous number of
discoveries are tested against a
range of questions across the
process from bench to bedsidebedside
Post-LaunchLaunchFilingPhase 3Phase 2Phase 1Pre-
ClinicalLead
OptimizationHit-to-LeadScreenDiscovery
![Page 5: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/5.jpg)
The Drug Development Process…only a few candidates make it through approval...…only a few candidates make it through approval...
Post-LaunchLaunchFilingPhase 3Phase 2Phase 1Pre-
ClinicalLead
OptimizationHit-to-LeadScreenDiscovery
![Page 6: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/6.jpg)
The Drug Development Process…to get one drug approved ...…to get one drug approved ...
• 10000 candidates enter the funnel• 10 years of development time• 2.6 Billion $ investment
Post-LaunchLaunchFilingPhase 3Phase 2Phase 1Pre-
ClinicalLead
OptimizationHit-to-LeadScreenDiscovery
Pharmaceutical Research and Manufacturers of America (PhRMA). Drug discovery and development: understanding the R&D process. Washington, DC: PhRMA; 2014Grabowksi H, Long G, Mortimer R. Recent trends in brand‐name and generic drug competition. J Med Econ. 2014;17(3):207‐214. doi:10.3111/13696998.2013.873723. Accessed March 2014Tufts Center for the Study of Drug Development (CSDD). Cost of developing a new drug. Briefing. Boston, Mass.: CSDD; November 2014. Accessed March 2015.
![Page 7: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/7.jpg)
The Drug Development Process…what do we need to prove...…what do we need to prove...
• Legal Basis for Drug Approval (US) • 1906 Pure Food and Drugs Act –– prohibited interstate trade of1906 Pure Food and Drugs Act prohibited interstate trade of
misbranded or adulterated food and drugs • 1938 Federal Food, Drug, and Cosmetic Act –– required that
drugs be shown safe prior to marketing g p g• 1962 Kefauver-Harris Amendments –– required that drugs be safe
and effective prior to marketing • Evidence of Effectiveness
• "substantial evidence" that a drug will have the effect it is claimed to have under proposed labeling.
• only source of substantial evidence are adequate and well- controlled studiesstudies
7
![Page 8: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/8.jpg)
The Drug Development Process…the goal: “global” approval”…
• Simultaneous global filing requires• Alignment on study design and key endpoints
…the goal: global approval …
• Usually obtained during an end-of-phase 2 meeting• Especially important for
• Indications with no approved products or no current guidance• First in class molecules
PMDAEMA
FDA
Health Canada
TGA
Post-LaunchLaunchFilingPhase 3Phase 2Phase 1Pre-
ClinicalLead
OptimizationHit-to-LeadScreenDiscovery
![Page 9: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/9.jpg)
The Drug Development Process…challenges for global approval……challenges for global approval…
Key agencies have different expectations for important elements of the clinical trials e gthe clinical trials, e.g• Endpoint harmonization• Patient population• Trial Duration• PRO validation• Long term follow up• Pediatric study commitment• Administration/Device developmentDependent on disease area maybe less interested in p y• Placebo vs active comparator
9
![Page 10: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/10.jpg)
The Drug Development Process…why is it important to choose the right endpoint……why is it important to choose the right endpoint…
• Supports the indication
S t th ffi l i th t ill b d i th• Supports the efficacy claims that will be covered in the product label
• Characterizes the products efficacy• Characterizes the products efficacy• Basis for promotional use • Inclusion in product monographs
10
![Page 11: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/11.jpg)
The Drug Development Process…once approved, time of exclusivity is limited……once approved, time of exclusivity is limited…
11
Pharmaceutical Research and Manufacturers of America (PhRMA). Drug discovery and development: understanding the R&D process. Washington, DC: PhRMA; 2014Grabowksi H, Long G, Mortimer R. Recent trends in brand‐name and generic drug competition. J Med Econ. 2014;17(3):207‐214. doi:10.3111/13696998.2013.873723. Accessed March 2014Tufts Center for the Study of Drug Development (CSDD). Cost of developing a new drug. Briefing. Boston, Mass.: CSDD; November 2014. Accessed March 2015.
![Page 12: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/12.jpg)
The Drug Development Process…the goal: access and reimbursement…
• US: • commercial payers/Medicare
…the goal: access and reimbursement…
commercial payers/Medicare• Part B/Part D
• Canada• Reimbursement negotiations in every province g y p
• Europe• Health Technology Assessment drives pricing and reimbursement (e.g.)
• UK (NICE), • Germany (AMNOG)• France (CT) • Italy (AIFA)• Spain
• Japan• Ministry of Health Labor and Welfare (MHLW)
• AustraliaAustralia • Pharmaceutical Benefits Assessment Committee (PBAC)
12
![Page 13: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/13.jpg)
The Drug Development Process…to get a good price you have to demonstrate added value……to get a good price you have to demonstrate added value…
• Degree of innovation• availability of existing productsy g p
• no adequate treatment to date • aimed at sub-groups of patients with absolute contraindications against
current medications• for whom new drugs represent the only feasible therapeutic option• which sub-groups of patients are resistant or non-responders to first line
therapy Wh i d t t t l d i t• When recognized treatments already exist• extent of therapeutic benefit will be evaluation
• Products offering better safety and efficacy or a better pharmacokinetic profilepharmacokinetic profile.
• Products that represent a pharmacological innovation - such as a new method of action - but no improvement over existing therapies.
• Products offering a technological innovation but not a therapeuticProducts offering a technological innovation but not a therapeutic advantage over existing products
13
![Page 14: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/14.jpg)
The Drug Development Process…demonstrate superiority….…demonstrate superiority….
• Study Designs• Double-blind active-controlled trials• Mixed treatment Network Meta-Analyses
• Choice of endpointsP ti t l t t• Patient relevant outcomes
• “Hard” outcomes (e.g. Mortality, cardiovascular events, fractures)• “relevant” patient reported outcomes (QoL)
14
![Page 15: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/15.jpg)
The Drug Development Process…start with designing an ambitious and realistic Target Product Profile (TPP)…Target Product Profile (TPP)…
Unmet need
Base case assumptions
Differen-tiation
Optimisticcase
Pessimistic case
Indication
Efficacy
SafetySafety
Tolerability
Dosing
15
![Page 16: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/16.jpg)
The Drug Development Process…let’s not forget why we are doing this……let s not forget why we are doing this…
• Focus• Serious illnesses• areas of high unmet medical need
• MissionT ti t• To serve patients
• Aspiration• use science and innovation to dramatically improve people's• …use science and innovation to dramatically improve people s
lives
16
![Page 17: Considering the End before the Beginning: Choosing the Correct Endpoints - Andreas Grauer, Amgen](https://reader034.vdocuments.net/reader034/viewer/2022051521/58ef20751a28ab41498b45d5/html5/thumbnails/17.jpg)
For more information about theFor more information about the marcus evans Pharma
S it iSummits series: [email protected]